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Since peptidyl diazomethyl ketones are useful irreversible inhibitors for inactivating cysteinyl proteinases in vitro and in vwo and in order to reveal 
their role, we set out to obtain selective and effective reagents for cathepsin S. A number of such derivatives with hydrophobic amino acid residues, 
such as valine, leucine and tryptophane in positions adjacent o the primary specificity site were synthesized and these provided inhibitors rapidly 
acting at high dilution. For example, 1 nM Z-Leu-Leu-Nle-CHN, inactivates cathepsin S with k 2nd = 4.6 x lo6 M-’ s-’ at pH 6.5,25”C. Similarities 
to the specificities of cathepsin L and calpain were evident. However, Z-Val-Val-NleCHN, is over 300 times more effective in inactivating S than 
L. On the other hand, Z-Phe-Tyr(t-Bu)CHN, is about lo4 more effective against L than S. Reagents are thus now available for a clear discrimination 
between these proteases. 
1. INTRODUCTION 
Cathepsin S is a cysteinyl proteinase originally puri- 
fied from bovine lymph nodes [l] and spleen [2-61, and 
was later found in kidney [7]. Confirmation of the dis- 
tinction of this protease from cathepsin L [3] was ini- 
tially provided by differences in proteolytic specificity 
[4], immunochemical properties and susceptibility to in- 
hibitors [3,8]. Studies on the collagenolytic proteases of 
rabbit spleen have also led to a similar conclusion [9,10]. 
Eventually the determination of the sequences of the 
bovine [11,12] and human [13,14] proteases established 
the distinct identity of cathepsin S. 
In the course of this work, the irreversible inhibitor, 
Z-Phe-Phe-CHN, was useful since its known inactiva- 
tion of cathepsin L at PM concentrations [8,15] was not 
matched in the case of cathepsin S [3,7], but a specific 
inhibitor for cathepsin S has not been available. The 
peptidyl diazomethyl ketones are inactivators of cys- 
teinyl proteases [16] and sequence variations can gener- 
ally provide some degree of specificity due to differences 
in their substrate-binding regions. They apparently owe 
their effectiveness to a substrate-like interaction of the 
peptide ketone group with the active-center -SH group, 
to provide an initial enzyme-inhibitor complex, a tran- 
sition-state analog [17]. We felt that a systematic study 
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with cathepsin S would probably yield more effective 
inhibitors and provide information about the substrate 
binding region. 
2. MATERIALS AND METHODS 
The peptidyl diazomethyl ketones were obtained from the corre- 
sponding peptide by reaction of its mixed anhydride with ethereal 
diazomethane as described [16,18]. The products were purified by 
chromatography on silica gel with chloroform containing increasing 
amounts of methanol. The purified inhibitors were generally obtained 
as solids, recrystallized, and their compositions confirmed by ele- 
mentary analysis. 
The new materials are Z-Leu-AlaCHN,, M.P. 9(1-91; Z-Leu-Leu- 
NleCHN,, M.P. 143-144; Z-Ile-MetCHN,, M.P. 143-144; Z-Trp- 
MetCHN,, M.P. 1533154; Z-Val-MetCHN,, M.P. 144-145; Z-Val- 
ValCHN,, M.P. 134136; Z-Val-NleCHN, M.P. 14&141; Z-Val-Val- 
NleCHN,, M.P. 244247; Z-Val-Trp-NleCHN,, M.P. 177-178; Z-Val- 
Val-TyrCHN,, M.P. 17&172; and Z-Ile-TrpCHN,, M.P. 156157. 
Z-Leu-NvaCHN,, Z-Leu-NleCHN,, and Z-Leu-Thr(tBu)CHN, did 
not crystallize and their structures were confirmed by mass deter- 
mination. Z-Phe-PheCHN, [18], Z-Phe-Tyr(tBu)CHN, [20], Z-Leu- 
LeuCHN, [19], Z-Leu-TrpCHN, [19], Z-Leu-Leu- TyrCHN, [19] and 
Z-y-methylLeu-TyrCHN, [19] were obtained as described. Z-Leu-Nle- 
aldehyde was purchased from Nova. 
For the evaluation of inhibitory properties, inhibitors were made up 
as lo-* M solutions in DMSO which usually could be diluted with 
water or 5% DMSO without precipitation. In the enzymatic studies 
the DMSO content was typically well below 1%. 
Cathepsin S was purified from bovine spleen [21] and activated 
before use with 5 mM DTT in 0.1 M PIPES buffer, pH 6.5, 75 mM 
in NaCl, 1 mM in EDTA, 0.01% Triton X-100 for 15 min at room 
temperature, then diluted 1:3 with buffer without DTT and stored on 
ice. It was assayed fluorimetrically with 4 x 10m5 M Z-Phe-Arg-AMC 
at 37”. 
Cathepsin L was purified from bovine kidney [21] and was activated 
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before use [22]. It was assayed with 2 x 10e5 M Z-Phe-ArgAMC in 0.1 
M acetate, pH 5.4, 1 mM EDTA, 0.01% Brij 35 and 1 mM DDT. 
Inhibitions were followed by removing timed aliquots from a mix- 
ture of inhibitor and cathepsin S at room temperature and the decay 
of enzyme activity was measured under first order conditions [18] in 
a range of inhibitor concentrations that avoided saturation effects. 
Replicate determinations were carried out and the results were within 
a 15% variation from the mean. In the case of Z-Val-ValCHN, a 
Dixon plot [23] was used to calculate K, by measuring initial velocities 
in mixtures of the inhibitor and 2 x 10e5 and 8 x 10T5 M Z-Phe- 
ArgAMC at 37’. The K, of Z-Leu-Nle-Aldehyde was similarly deter- 
mined, but the higher substrate concentration was 10s4 M. 
3. RESULTS AND DISCUSSION 
Our earlier work on the inactivation of cysteinyl pro- 
teinases with peptidyl diazomethyl ketones was directed 
largely at cathepsins B and L [l&20] and the calcium- 
activated proteinase, calpain [19]. In terms of their 
specificities, the first two, cathepsin B and L, resemble 
the classical cysteinyl proteinase, papain, in that they 
effectively bind an aromatic residue in the S, site of the 
substrate binding region, making use of the terminology 
of Schecter and Berger [24,25] who first demonstrated 
this binding preference. When the specificity of calpain 
was explored with inhibitors, it was found that the S, 
binding region does not show affinity for aromatic side 
chains, but has a preference for aliphatic side chains 
such as leucine. Cathepsin L, in contrast, is susceptible 
to inhibitors which contain either an aromatic residue 
or leucine in the P2 position [19]. 
Our observations with cathepsin S and peptidyl di- 
azomethyl ketones began with Z-Phe-PheCHN, whose 
Table I 
Rates of Inactivation of Cathepsin S, pH 6.5 
Diazomethyl Cone r1/2 
Ketone (M) (min) 
$5 (M?s-‘) 
Z-Leu-Leu-NleCHN, 1 x 1o-9 1.25 0.0092 9.2 x lo6 
Z-Val-Val-NleCHN, 1 x 1o-9 2.5 0.0046 4.6 x lo6 
Z-Leu-Leu-TyrCHN, 1 x lo+ 5.5 0.0021 2.1 x lo6 
Z-Trp-MetCHN, 1 x 1o-8 3.0 0.00385 3.8 x lo5 
Z-Val-Val-TyrCHN, 5 x lo+ 6.75 0.0017 3.4 x lo5 
Z-Leu-NleCHN, 1 x lo+ 3.4 0.0034 3.4 x lo5 
Z-Leu-NvaCHN, 1 x 10-s 4.5 0.0026 2.6 x 10’ 
Z-Val-Trp-NleCHN* 1 x lo-* 5.7 0.002 2.0 x lo5 
Z-Leu-LeuCHN, 2 x 1o-8 8.6 0.0013 6.7 x lo4 
Z-Val-NleCHN, 3 x lo-* 5.8 0.0020 6.6 x lo4 
Boc-Lys-Leu-TyrCHN, 1 x lo-’ 2.9 0.004 4.0 x lo4 
Z-Val-MetCHN, 1 x lo-’ 3.5 0.0033 3.3 x lo4 
Z-Leu-TrpCHN, 2 x lo-’ 2.6 0.0044 2.2 x lo4 
Z-Leu-AlaCHN, 1 x lo-’ 5.5 0.0021 2.1 x Iti 
Z-y-MeIeu-TyrCHN, 4 x lo-’ 3.85 0.003 7.5 x lo3 
Z-Leu-Thr(t-Bu)CHN, 1 x 1o-6 3.5 0.0033 3.3 x 103 
Z-Val-ValCHN, 1 x lo-’ 47.0 0.000246 2.5 x 10’ 
Z-Ile-MetCHN, 1 x 1o-6 5.4 0.0021 2.1 x lo3 
Z-Phe-PheCHN, 2 x 1o-6 6.4 0.0018 9.1 x lo2 
Z-Ile-TrpCHN, 4 x 1o-6 3.45 0.0033 8.4 x 10’ 
Z-t-Leu-TyrCHN, 1 x 1o-4 1.6 0.0072 72 
Z-Phe-Tyr(t-Bu)CHN, 2 x 1o-5 19.25 0.0006 30 
relatively low reactivity, 900 M-’ . s-’ for the enzyme 
from bovine spleen [6] was confirmed. The possibility 
was considered that this reflected a poor ability to bind 
an aromatic side chain in the S, and/or S, subsites as has 
been observed with Phe [15] or Trp [20] in P, in the case 
of cathepsin B or with aromatic residues in P, in the case 
of calpain [19]. When a single aromatic residue was 
present in P, (even Trp) a modest reactivity was observ- 
able as in the case of Z-Leu-TrpCHN, (Table I) and, in 
P,, a favorable binding was evident, cf. Z-Trp- 
MetCHN, compared to Z-Val-MetCHN, (Table I). 
Thus, no difficulty in binding at least an inhibitor with 
a single aromatic amino acid was evident. 
We then examined inhibitors containing aliphatic 
side-chains, both straight-chained and branched, in Pi, 
P2, and P,. In P, amino acids with linear side chains such 
as norvaline, methionine, norleucine provide inhibitors 
with good reactivity as shown by a number of entries 
in Table I. 
The P, variations provided some favorable results 
(Table I) with Leu, Val, and Trp, but less with Ile, 
y-methyl-Leu, and t-Leu. For example, Z-Trp- 
MetCHN, inactivates cathepsin S with a 
kznd = 3.8 x lo5 M-’ * SC’ in contrast to Z-Ile-MetCHN,, 
for which kznd = 2.1 x lo3 M-’ . s-l. The effectiveness of 
leucine in P2 is reminiscent of results with cathepsin L 
[19]; the affinity of valine for cathepsin S was indicated 
in the work of Brijmme et al. [8] with a number of 
substrates and inhibitors. Val and Leu seem almost 
equally effective in P2 and P, as evidenced by our results 
with tripeptide derivatives (Table I), several of which act 
rapidly at nM concentrations. 
The low reactivity of Z-Val-Val-CHN, was unex- 
pected. This is not due to poor affinity to cathepsin S 
since competition of substrate hydrolysis [23] showed 
that this derivative is a good reversible inhibitor with 
K, = 0.9 ,uM. This value is in the middle of the range of 
K, values (0.3-2.2 PM) measured for six inhibitors of 
cathepsin L [19]. It may be that this substance is bound 
largely at S2 and S, and thus the diazomethylketone 
group is too remote to interact with the -SH group. 
Our studies have examined a limited number of se- 
quences but the results demonstrate the large variation 
of inhibitory effectiveness for cathepsin S of structures 
constructed with peptidyl diazomethyl ketones. This 
study converges with earlier work in which cathepsin L 
and calpain [ 191 were shown to be susceptible to deriva- 
tives containing Leu in P, and P,. However, there re- 
main some useful distinctions. Cathepsin S was found 
to be resistant to Z-Phe-Tyr(t-Bu)CHN, and this sub- 
stance remains a unique inhibitor of cathepsin L. 
Cathepsin S will bind an aromatic residue in S, like 
cathepsin L and in dinstinction to calpain. 
Some similarities and differences in the response of 
cathepsins L and S to peptidyl diazomethyl ketones are 
listed in Table II. Although not all of the new deriva- 
tives have been tested with cathepsin L, it is of interest 
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Table II 
Some of the major differences and similarities in the rates of inactiva- 
tion of cathepsin S and L by peptidyl diazomethyl ketones 
Inactivation rate (M-’ . SC’) 
Similarities 
Z-Leu-Leu-TyrCHN, 
Cathepsin S Cathepsin L 
(PH 6.5) (PH 5.4) 
2.1 x IO6 (a) 1.5 x lo6 (b) 
1.3 x lo5 (c) 
Z-Trp-MetCHN, 
Z-Leu-TrpCHN, 
Differences 
3.8 x lo5 (a) 
2.2 x lo4 (a) 
1.4 x lo5 (a) 
1.2 x lo4 (b) 
Z-Tyr-AlaCHN, 1.7 x 10’ (d) 1.2 x lo5 (d) 
Z-Val-Val-NleCHN, 4.6 x lo6 (a) 1.2 x IO4 (a) 
Z-Phe-Tyr(t-Bu)CHN, 30 (a) 2 x lo5 (e) 
(a) This work; (b) ref. 19; (c) ref. 27; (d) ref. 28; (e) ref. 20. 
that Z-Val-Val-NleCHN, is considerably more effective 
(380-fold) in inactivating cathepsin S than L. 
Radiolabelling of active cysteinyl proteinases in cells 
and tissues using ‘25I derivatives of Tyr-containing di- 
azomethyl ketones has become a useful tool in their 
study. The use of Z-[1251]Tyr-AlaCHN, to label cathep- 
sins B, S, and L [28,29] and Z-Leu-Leu-[“‘IJTyrCHN, 
to label calpain and cathepsin L, and S [30,31] can be 
made more selective by the use of control inhibitors. 
Our results indicate that if the presence of both cathep- 
sins S and L are a problem, prior treatment with Z- 
Phe-Tyr(t-Bu)CHN, will eliminate L and will leave 
functioning cathepsin S available for observation and 
iodination. It has to be kept in mind when using irre- 
versible inhibitors on cells, that kinetic differences may 
disappear with high concentrations and long incuba- 
tions, Further discussion of the combined use of inhib- 
itors may be found in [26]. 
An independent line of study involving peptidyl alde- 
hydes as reversible inhibitors of calpain has led to Z- 
Leu-Nle-aldehyde [32] and similar structures with hy- 
drophobic side chains [33]. In view of this type of pep- 
tide portion, it seemed probable to us that these would 
also inhibit cathepsin S, as has been shown earlier for 
cathepsin L [34]. In fact, we found Z-Leu-Nle-aldehyde 
to be an effective inhibitor of cathepsin S, with 
K, = 2 x lo-’ M ( ave. of 4 runs). Therefore the results 
obtained with such inhibitors and the interpretation of 
these results to demonstrate a role for calpain should be 
reexamined. Such reagents could be used in conjunction 
with irreversible inhibitors as discussed above to obtain 
a more secure interpretation of their site of action. 
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